Tag: Yuhan

Yuhan

Latest News

Yuhan inks $80.9M deal with Gilead Sciences for HIV drug ingredients

Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the treatment of human immunodeficiency virus (HIV), the Korean drugmaker announced in an electronic disclosure on Friday.

2024.9.20

Yuhan Corporation Central Research Institute [YUHAN]

Yuhan’s new lung cancer drug set for global market with Johnson & Johnson deal

A new lung cancer drug from pharmaceutical firm Yuhan Corporation, led by CEO and President Wook Je Cho, has emerged as a treatment with big potential.

2024.7.19

Most popular

Yuhan's lung cancer drug Leclaza [YUHAN]

Yuhan to offer lung cancer drug for free

Pharma firm Yuhan will supply its domestically-developed lung cancer drug Leclaza for free until it is covered by national health insurance in Korea.

2023.7.11

Yoon Tae-won, CEO of Yuhan USA, speaks in an interview with reporters on Jan. 9 at the BEI San Francisco hotel, on the sidelines of the annual J.P. Morgan Healthcare Conference in the city. [PARK EUN-JEE]

[INTERVIEW] Yuhan USA is searching for its next promising investment

Yuhan, a Seoul-based biopharmaceutical company best known for its licensing of a novel lung cancer treatment called lazertinib, sold under brand Leclaza, has clinched a deal with Yansen to export the drug and is now looking for its next target.

2023.1.11

Yuhan's disc treatment gets nod for Phase 3 trials

YH14618, a degenerative disc disease treatment candidate that was licensed by Yuhan to New York-based Spine Biopharma, won approval to start Phase 3 clinical trials in the United States, the Korean company said Monday.

2022.4.11

Yuhan's YH35324 approved for Phase 1 clinical trials

Yuhan’s YH35324 allergy treatment candidate won approval for Phase 1 clinical trials in Korea, the pharmaceutical company said Monday.

2021.7.19

Yuhan authorized to sell novel lung cancer drug lazertinib

Yuhan’s lazertinib is the 31st new drug to receive market authorization in Korea. This is also the first time in three years that the drug regulator had granted such approval, since July 2018.

2021.1.18

A researcher is working in the lab of the pharmaceutical company Yuhan. [YUHAN]

Yuhan teams up with AbClon to develop Covid treatment

Korea’s leading pharmaceutical company Yuhan is officially in the race to develop a Covid-19 treatment, the company announced Monday.

2020.7.27